Global Chidamide Market Size, Share and Trends Analysis Report, By Application (PECL Treatment and Cancer Treatment), Forecast Period (2022-2028)

The global chidamide market is anticipated to grow at a CAGR of 3.2% during the forecast period (2022-2028). The increasing prevalence of cancer globally is a major driving factor for the chidamide industry growth. Furthermore, the market is likely to be driven by continuing clinical trials for chidamide and an increased need for new treatment choices over the forecast period. Rising rates of cancers such as ovarian cancer, breast cancer, and lung cancer are expected to fuel demand for chidamide. Additionally, rising knowledge of various treatment alternatives is expected to support the market’s growth in the near future.

HBI-8000 is a subtype-selective benzamide HDAC (histone deacetylase) inhibitor. Chidamide is also known as CS055. In colon cancer cells, it raises histone H3 acetylation levels. It’s a promising treatment for relapsed and refractory peripheral T-cell lymphoma (PTCL) cancer, as well as other cancers such as hepatocellular carcinoma, haematological cancer, and bladder tumour. Chidamide not only prevents tumour cells from proliferating but also boosts cellular immunity in a variety of malignancies. Since the global burden of cancer across the globe is increasing, it positively impacts the chidamide market.

The PECL Treatment uses chidamide to stop tumour cells from dividing and developing. Chidamide Sales interacts with topoisomerase II, an enzyme that helps control the structure of DNA. When this happens, the cancer cells are unable to grow. Chidamide Sales are used in PECL Treatment to prevent tumour cells from proliferating and developing. It aids in the binding of topoisomerase II, an enzyme that aids in the control of DNA structure. When this happens, the cancer cells are unable to grow.

Some major players in the market include Eisai Co., Ltd., GNT Biotech Medicals Corp., HUYA Bioscience International, Shenzhen Chipscreen Biosciences Co., Ltd., and Spectrum Pharmaceuticals, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

In November 2021, a research study was conducted, Chidamide with Immunotherapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma, Chidamide has been licenced in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (Chidamide, a novel histone deacetylase inhibitor). Tirelizumab, a monoclonal antibody, has been licenced in China for the treatment of platinum-containing chemotherapy failure in patients with high PD-L1 expression who have locally progressed or metastatic Urothelial carcinoma (Tirelizumab, BGB-A317 is an investigational humanised IgG4 anti-PD-1 monoclonal antibody). The goal of this trial was to see how well Chidamide worked with Immunotherapy in patients who had recurrent or metastatic Urothelial carcinoma after receiving platinum-based chemotherapy.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Eisai Co., Ltd., GNT Biotech Medicals Corp., HUYA Bioscience International, Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Chidamide Market Report by Segment

By Application

• PECL Treatment
• Cancer Treatment

Global Chidamide Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa